Epigral Ltd. (EPIGRAL) — Tipsheet

Epigral enters epoxy resins with two Dahej plants, capex undisclosed

Tipsheet Editorial — Mon, 27 Jul 2026 14:18:05 GMT

Board approves a 125,000 TPA epoxy resin plant and a multi-purpose unit, both to be commissioned by H2FY28. The investment amount is not disclosed, leaving scale unmeasured.

What’s new

Board cleared two greenfield projects at Dahej: an epoxy resin plant and a multi-purpose intermediate facility.
Epoxy resin (125K TPA) is a new product line, targeting renewable energy, electronics, and infrastructure.
No investment amount was disclosed, limiting assessment of financial impact.

Why it matters

Epigral is pushing deeper into downstream specialty chemicals with a new epoxy resin stream in a high-growth market. But without a capex figure, investors can't gauge whether the spend is modest relative to its ₹4,772 cr market cap or a stretch on its 0.25 debt/equity ratio.

What we’re watching

Disclosure of the total investment in future filings - the missing piece for return analysis.
Execution progress toward H2FY28 commissioning; any delays could signal cost overruns.
Debt/equity movement - currently low, the capex could raise it meaningfully.

The full read

Epigral is making its biggest strategic move in years: a 125,000 TPA epoxy resin plant and a multi-purpose intermediate facility, both at Dahej and due online in H2FY28. Epoxy resin is a new product line for the company, opening a door into renewable-energy, electronics, and infrastructure supply chains that command higher margins than basic commodities. The multi-purpose plant deepens backward integration, consuming inputs from Epigral's own epichlorohydrin and chlorotoluene lines. The quarterly numbers (₹709 cr revenue, 25% EBITDA margin) were routine. What matters now is the missing capex figure. Without it, the market can't weigh the scale of the spend against a ₹4,772 cr market cap and a 0.25 debt/equity ratio. The intent is clear; the price tag isn't.

Primary source: BSE · NSE

Epigral bets ₹600 cr on epoxy resins in strategic pivot

Tipsheet Editorial — Mon, 27 Jul 2026 14:15:00 GMT

The chemicals company posted a 25% profit jump in Q1 and announced a capex equal to 12% of market cap to enter epoxy resins, drawing over half the input value from internal production.

What’s new

Epigral board approved ₹600 cr capex for epoxy resin capacity of 125 KTPA and derivatives.
Q1 net profit rose 25% YoY to ₹99 cr; revenue up 15% to ₹709 cr; EBITDA margin 25%.
Over 50% of raw material for the project will come from existing epichlorohydrin and caustic soda.

Why it matters

This is the biggest single bet in Epigral's recent history. The capex is 12% of market cap and shifts the company into higher-value epoxy resins, a market driven by renewable energy and electronics. The backward integration gives it a structural cost edge over peers who buy inputs.

What we’re watching

Pilot plant by Q2 FY27 -- a go/no-go test for the full-scale project.
How the debt-equity ratio (~0.25) evolves as the capex gets funded.
Customer traction from the automotive and renewable energy sectors.

The full read

Epigral posted a clean set of Q1 numbers: net profit up 25% to ₹99 crore on revenue of ₹709 crore, with an EBITDA margin of 25%. But the real news is the board's decision to spend ₹600 crore (equal to 12% of market cap) on a strategic entry into epoxy resins and formulations. The 125,000-tonne-per-annum plant will sit behind Epigral's existing epichlorohydrin and caustic soda lines, with over half the raw material value sourced internally. That backward integration gives it a margin advantage that pure-play epoxy makers cannot match. The first milestone is a pilot plant by Q2 FY27; commercial production is set for H2 FY28. The debt ratio is low at 0.25, so the funding math works even if part of the outlay is debt-financed. Execution risk is real, but this is the sort of pivot that rewrites a company's growth profile when it works. It won't be immediate, and the open question is whether customer approvals come through on schedule. But the direction is clear.

Primary source: BSE · NSE

Epigral Q1: Revenue up 16%, adjusted PAT jumps 24%

Tipsheet Editorial — Mon, 27 Jul 2026 13:59:22 GMT

Excluding a one-time deferred tax credit in the base quarter, profit rose on volume recovery and sequential margin improvement. The company also incorporated a subsidiary for chemical manufacturing.

What’s new

Revenue of ₹705.36 cr, up 16% YoY from ₹606.54 cr.
Reported PAT fell to ₹99.18 cr from ₹160.41 cr due to one-time tax credit in base quarter; adjusted PAT rose ~24%.
Incorporated wholly owned subsidiary Epigral Advanced Material Limited on July 7 for chemical manufacturing.

Why it matters

The adjusted profit growth and sequential margin improvement suggest Epigral's underlying business is recovering on volumes and pricing. The new subsidiary signals expansion into advanced materials, though financial details are not yet disclosed.

What we’re watching

Sustenance of volume and margin recovery in coming quarters.
Any capital allocation plan for the new subsidiary.
Q2 commentary on demand trends in key chemical segments.

The full read

Epigral's June quarter revenue hit ₹705.36 crore, up 16% from ₹606.54 crore a year ago. Reported profit fell to ₹99.18 crore from ₹160.41 crore, but the base quarter had a one-time deferred tax credit of ₹80.67 crore. Excluding that, adjusted PAT rose roughly 24%. More important, EBITDA margins improved sequentially, a sign that volume recovery and cost control are gaining traction. The incorporation of a new subsidiary for chemical manufacturing is an early administrative step — no financial commitment yet. For a company with a trailing P/E of 14.4 and debt-to-equity of 0.25, even modest operational improvement buys credibility. The next test: whether this trajectory holds through Q2.

Primary source: BSE · NSE

Epigral logs 16% revenue growth in Q1; PAT falls on one-time credit base effect

Tipsheet Editorial — Mon, 27 Jul 2026 13:55:34 GMT

Revenue hit ₹705 cr, EBITDA margin in line with 25% guidance. PAT slipped to ₹99.18 cr as last year's ₹80.67 cr deferred tax credit didn't repeat.

What’s new

Revenue grew 16% YoY to ₹705 cr, meeting management's EBITDA margin guidance of 25%.
PAT dropped to ₹99.18 cr from ₹160.41 cr due to absence of ₹80.67 cr one-time deferred tax credit.
Incorporated wholly-owned subsidiary Epigral Advanced Material for chemical manufacturing.

Why it matters

Steady revenue growth and margin discipline confirm operational stability. PAT decline is purely a base-effect from a non-recurring tax benefit, not an operational weakness. The new subsidiary signals expansion but lacks material financial details for now.

What we’re watching

Whether full-year EBITDA margin remains near 26%.
Details on capex plans for the new subsidiary.
Any impact from chemical pricing cycles on revenue momentum.

The full read

Epigral delivered steady growth in Q1 with revenue climbing 16% to ₹705.36 crore, while EBITDA margin held at about 26% — right in line with the 25% the company guides for. The sharp drop in profit to ₹99.18 crore from ₹160.41 crore looks alarming only until you see last year's number carried an ₹80.67 crore deferred tax credit that didn't repeat. Exclude that, and the underlying business is stable. The incorporation of a wholly-owned subsidiary for chemical manufacturing is a small strategic step, but without capex or revenue projections it's a footnote for now. This is a routine quarterly filing that confirms the operational trajectory. No surprises. No model revisions needed.

Primary source: BSE · NSE